# Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

> **NCT05278338** · PHASE2 · UNKNOWN · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** JMT103
- **DRUG:** Denosumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05278338
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-21
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278338, "Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05278338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*